<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265951</url>
  </required_header>
  <id_info>
    <org_study_id>RF-1070471</org_study_id>
    <nct_id>NCT03265951</nct_id>
  </id_info>
  <brief_title>Ramelteon for Complex Insomnia in Veterans With PTSD</brief_title>
  <acronym>DORMI</acronym>
  <official_title>A Pilot, Randomized, Double-blind, Placebo Controlled, Trial of Ramelteon for CPAP Non-Adherent Veterans With PTSD and Complex Insomnia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The VA Western New York Healthcare System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obstructive sleep apnea is commonly reported in Veterans with post-traumatic stress disorder,&#xD;
      which can potentiate symptoms of anxiety and depression, daytime symptoms and worsen&#xD;
      nightmares. Continuous positive airway pressure is the most effective therapy but adherence&#xD;
      to treatment is suboptimal. The overarching theme of the proposal is to compare usual care to&#xD;
      Ramelteon, in a randomized, clinical trial, investigating the effectiveness of physiological&#xD;
      versus pharmacological intervention on sleep quality of life, insomnia severity and CPAP&#xD;
      adherence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the overall improvement in PTSD symptomatology with CPAP therapy, adherence to CPAP&#xD;
      is far worse in Veterans with PTSD (41%) compared to the general population with OSA (70%).&#xD;
      Among the factors associated with CPAP non-adherence is the coexistence of insomnia. Complex&#xD;
      insomnia defined as the coexistence of comorbid insomnia ans OSA is a frequent diagnosis in&#xD;
      military personnel with combat exposure. Similar to prior reports of patients with OSA&#xD;
      without PTSD, comorbid insomnia can create a barrier to CPAP therapy. Ramelteon (TAK-375),&#xD;
      approved by the Food and Drug Administration for the treatment of insomnia with sleep onset&#xD;
      abnormalities, is a neurohormone that functions as a melatonin receptor agonist targeting the&#xD;
      MT1 and MT2 receptors located in the suprachiasmatic nucleus of the hypothalamus which&#xD;
      regulates the circadian rhythm of the 24-hour sleep-wake cycle.The goal is to test the&#xD;
      hypothesis that the administration of insomnia therapy-ramelteon- significantly improves&#xD;
      treatment outcomes in Veterans with PTSD and complex insomnia compared with placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of response&#xD;
  </why_stopped>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pittsburgh Sleep Quality Index</measure>
    <time_frame>12 weeks post randomization</time_frame>
    <description>Quality of life</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PCL-5</measure>
    <time_frame>12 weeks post randomization</time_frame>
    <description>PTSD Checklist</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ISI</measure>
    <time_frame>12 weeks post randomization</time_frame>
    <description>Insomnia Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPAP adherence</measure>
    <time_frame>12 weeks post randomization</time_frame>
    <description>CPAP adherence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Ramelteon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramelteon 8 mg po at bedtime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>education brochure about sleep hygiene</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramelteon</intervention_name>
    <description>8 mg once daily administered within 30 minutes of bedtime</description>
    <arm_group_label>Ramelteon</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>education brochure about sleep hygiene</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤70 years old&#xD;
&#xD;
          -  Diagnosis of PTSD as determined by the intake conducted through the PTSD Clinic or the&#xD;
             Mental Health Clinic&#xD;
&#xD;
          -  Documented obstructive sleep apnea by polysomnography (AHI≥5 or more/hour)&#xD;
&#xD;
          -  CPAP non adherence defined as less than 70% of nights with &gt;4h CPAP use despite&#xD;
             addressing modifiable barriers for CPAP adherence&#xD;
&#xD;
          -  Psychotherapeutic treatment stable for at least 4 weeks prior to randomization&#xD;
&#xD;
          -  Capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical:&#xD;
&#xD;
               -  Acute or unstable chronic medical illness&#xD;
&#xD;
               -  History of narcolepsy and/or cataplexy Use of any of these medications:&#xD;
                  Fluvoxamine, fluconazole (Diflucan), itraconazole (Sporanox), and ketoconazole&#xD;
                  (Nizoral); cimetidine (Tagamet); clarithromycin (Biaxin); fluoroquinolones&#xD;
                  including ciprofloxacin, levofloxacin (Levaquin), moxifloxacin (Avelox),&#xD;
                  norfloxacin (Noroxin), ofloxacin (Floxin), others; HIV protease inhibitors&#xD;
                  including indinavir (Crixivan), nelfinavir (Viracept), and ritonavir (Norvir, in&#xD;
                  Kaletra); nefazodone; rifampin&#xD;
&#xD;
               -  Treatment for seizure disorders&#xD;
&#xD;
               -  Pregnant or lactating&#xD;
&#xD;
               -  History of clinically significant hepatic impairment&#xD;
&#xD;
               -  History of hypersensitivity, intolerance, or contraindication to ramelteon&#xD;
&#xD;
               -  Unwilling to try or use CPAP&#xD;
&#xD;
        Psychiatric/Behavioral:&#xD;
&#xD;
          -  Diagnosis of current schizophrenia or schizoaffective disorder&#xD;
&#xD;
          -  Diagnosis of a substance dependence/abuse disorder in the past year&#xD;
&#xD;
          -  Severe psychiatric instability or severe situational life crises, including evidence&#xD;
             of being actively suicidal or homicidal, or any behavior which poses an immediate&#xD;
             danger to patient or others&#xD;
&#xD;
          -  Diagnosis of bipolar disorder&#xD;
&#xD;
          -  Consumption of more than two alcoholic beverages per night&#xD;
&#xD;
          -  Receiving behavioral or pharmacological treatment for insomnia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali El Solh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The VA Western New York</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center in Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 25, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Ali El Solh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sleep apnea, PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

